Discover 1,474 paid clinical trials in Kent, Washington. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,474
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
for
Alzheimer Disease, Dementia, Plaque, Amyloid
Location: Tacoma WA, Bellevue WA, Boise ID, Santa Rosa CA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 55+
Code: NCT07602582
Phase 3, Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
for
Advanced Breast Cancer
Location: Tacoma WA, Glendale CA, Los Angeles CA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06380751
Phase 3, Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
for
Non-small Cell Lung Cancer
Location: Tacoma WA, Edmonton, Walnut Creek CA, Las Vegas NV,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06350097
Phase 3, Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
for
Non-Small Cell Lung Cancer
Location: Tacoma WA, Wenatchee WA, Vancouver WA, Vancouver,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06357533
Phase 3, Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Get alerts for new trials in your area by subscribing now
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
for
Breast Cancer
Location: Tacoma WA, Sacramento CA, Saskatoon, Regina,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06103864
Phase 3, Recruiting
Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema
for
Center-involved Diabetic Macular Edema (CI-DME)
Location: Tacoma WA, Olympia WA
Sponsor: ZeaVision, LLC
Sex: All
Age: 18 - 70+
Code: NCT03866005
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
for
Myelodysplastic Syndrome
Location: Issaquah WA, Seattle WA, Edmonds WA, Post Falls ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06577441
Phase 2, Recruiting
Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
for
Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8,
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
for
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8,
Location: Issaquah WA, Seattle WA, Edmonds WA, Hood River OR,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06498635
Phase 3, Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
for
Acute Myeloid Leukemia
Location: Issaquah WA, Seattle WA, Edmonds WA, Post Falls ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06672146
Phase 2, Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Issaquah WA, Seattle WA, Edmonds WA, Vancouver WA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT06876714
Phase 3, Recruiting
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
for
Lung Non-Small Cell Carcinoma
Location: Issaquah WA, Seattle WA, Edmonds WA, Post Falls ID,